International Ophthalmology

, Volume 30, Issue 1, pp 57–61 | Cite as

Role of intravitreal bevacizumab in the management of Eales’ disease

  • Bhuvan Chanana
  • Raj Vardhan Azad
  • Sourabh Patwardhan
Original Paper

Abstract

Purpose To evaluate the role of intravitreal bevacizumab in the treatment of Eales’ disease. Study design Retrospective, interventional case series. Methods Two patients with proliferative Eales’ disease were managed with an intravitreal injection of bevacizumab (1.25 mg). The presence of persistent retinal neovascularization despite adequate laser photocoagulation caused recurrent episodes of vitreous hemorrhage in the first patient. The second patient had florid retinal and disc neovascularization with a dispersed vitreous bleed, which prevented laser therapy. Both patients were followed up for 6 months. Results Rapid regression of the retinal neovascularization and clearing of the vitreous hemorrhage were observed in both cases following intravitreal bevacizumab therapy, allowing laser photocoagulation. In both patients, the visual acuity improved, and no signs of recurrence were observed 6 months post-treatment. Conclusion Intravitreal bevacizumab injections may be effective as an adjunctive or alternative treatment of retinal neovascularization in Eales’ disease, where inadequate visualization precludes laser photocoagulation. This approach may also be useful in avoiding vitreoretinal surgical intervention in certain cases. Intravitreal bevacizumab was well tolerated by our patients, and no adverse effects were observed.

Keywords

Bevacizumab Eales’ disease Retinal neovascularization Vitreous hemorrhage 

References

  1. 1.
    Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611. doi:10.1210/er.2003-0027 CrossRefPubMedGoogle Scholar
  2. 2.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372. doi:10.1016/j.ophtha.2005.11.019 CrossRefPubMedGoogle Scholar
  3. 3.
    Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU (2007) Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149. doi:10.1097/IAE.0b013e31802eff83 CrossRefPubMedGoogle Scholar
  4. 4.
    Batioğlu F, Astam N, Ozmert E (2008) Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol 28:59–61. doi:10.1007/s10792-007-9105-2 CrossRefPubMedGoogle Scholar
  5. 5.
    Ahmadieh H, Moradian S, Malihi M (2005) Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab. Int Ophthalmol 26:191–193. doi:10.1007/s10792-007-9036-y CrossRefPubMedGoogle Scholar
  6. 6.
    Haritoglou C, Kook D, Neubauer A et al (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999–1005. doi:10.1097/01.iae.0000247165.38655.bf CrossRefPubMedGoogle Scholar
  7. 7.
    Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113(1695):e1–15PubMedGoogle Scholar
  8. 8.
    Atmaca LS, Idil A, Gunduz K (1993) Visualization of retinal vasculitis in. Eales’ disease. Ocul Immunol Inflamm 1:41–48. doi:10.3109/09273949309086536 CrossRefGoogle Scholar
  9. 9.
    Spitznas M, Meyer-Schwickerath G, Stephan B (1975) The clinical picture of Eales’ disease. Graefes Arch Clin Exp Ophthalmol 194:73–85. doi:10.1007/BF00413371 CrossRefGoogle Scholar
  10. 10.
    Adamis PA, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111–118. doi:10.1097/00006982-200502000-00001 CrossRefPubMedGoogle Scholar
  11. 11.
    Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R (2006) Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand 84:834–835. doi:10.1111/j.1600-0420.2006.00779.x CrossRefPubMedGoogle Scholar
  12. 12.
    Küçükerdönmez C, Akova YA, Yilmaz G (2008) Intravitreal injection of bevacizumab in Eales disease. Ocul Immunol Inflamm 16:63–65. doi:10.1080/09273940801923903 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Bhuvan Chanana
    • 1
  • Raj Vardhan Azad
    • 1
  • Sourabh Patwardhan
    • 1
  1. 1.Dr. Rajendra Prasad Centre for Ophthalmic SciencesAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations